Schizophrenia News and Research

Latest Schizophrenia News and Research

NARSAD announces 2010 Independent Investigator grants for innovative researchers

NARSAD announced its 2010 Independent Investigator grants totaling in excess of $4.1 million, which will support 42 innovative researchers at the leading edge of discovery within neuroscience and psychiatry. Since 1987 NARSAD has awarded more than $261.6 million in 3,832 grants to 3,132 scientists around the world.

24 Aug 2010

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Neuralstem, Inc. announced that it received notification that the United States Patent and Trademark Office (USPTO) has upheld the patentability, without amendment, of all claims in U.S. Patent No. 5,753,506 and intends to issue a reexamination certificate in due course. This patent describes methods of culturing and expanding neural stem cells.

19 Aug 2010

Deficiencies in DNA loop formation can cause multiple diseases: Research

The genes that are responsible for maintaining each cell type form DNA loops that link control elements for these genes. This surprising genome structure is generated and reinforced by two essential protein complexes that bridge the loops and contribute to proper gene regulation.

19 Aug 2010

Maternal stress contribute to an elevated risk for depression in offspring: Research

For more than a century, clinical investigators have focused on early life as a source of adult psychopathology. Although the hypothesized mechanisms have evolved, a central notion remains: early life is a period of unique sensitivity during which experience confers enduring effects.

19 Aug 2010

Maternal stress associated with increased risk of schizophrenia in male offspring

18 Aug 2010

NIH awards Brain Plasticity $3.65M to improve cognitive function in people with schizophrenia

Brain Plasticity Inc., a new technology incubator dedicated to the discovery and development of novel technologies that harness the basic principles of brain plasticity to improve the lives of people with neurological and psychiatric disorders, was recently awarded $3.65 million dollars in two separate grants from the National Institutes of Health (NIH).

18 Aug 2010

Brain stimulation may improve thinking in people with schizophrenia

Mild electrical stimulation to the brain could improve thinking and reduce auditory hallucinations in people with schizophrenia and schizo-affective disorder, researchers from the University of New South Wales (UNSW) have found.

17 Aug 2010

Depressive Cognition Scale questions can detect cognitive symptoms of early depression

A diagnostic test of eight short questions designed by Jaclene Zauszniewski from the Frances Payne Bolton School of Nursing at Case Western Reserve University can be used to detect depressive thinking patterns that lead to clinical depression in women who care for an adult family member with a serious mental illness.

17 Aug 2010

Cortex second-quarter net loss decreases to $0.04 per share

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $2,454,000, or $0.04 per share, for the quarter ended June 30, 2010, compared with a net loss applicable to common stock of approximately $2,778,000, or $0.06 per share, for the corresponding prior year period.

16 Aug 2010

ARYx secures bridge financing, reports decrease in net loss to $3.6M for second-quarter 2010

ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.

16 Aug 2010

Recent research on schizophrenia published in journal Current Directions in Psychological Science

It has been nearly a century since the term "schizophrenia" was first used to describe what was then considered a hopeless and incurable disorder of thought and emotion. Schizophrenia is still baffling to both scientists and the general public, but it is no longer considered hopeless. Significant advances have been made on several fronts in fathoming and combating this debilitating mental illness-from genetics to neuroscience to the psychosocial aspects of the disorder.

16 Aug 2010

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.

16 Aug 2010

Management of therapy-resistant schizophrenia

The psychotic symptoms of up to 30% of schizophrenic patients do not respond adequately to treatment with antipsychotic drugs, other than clozapine. These refractory patients are generally among the most disabled of all people with schizophrenia and require special assessment and treatment.

13 Aug 2010

EUROPEAN BIOTECHNICA AWARD finalists announced

The names of the finalists in this year's EUROPEAN BIOTECHNICA AWARD have been announced. The companies Addex Pharmaceuticals (Switzerland), Apeiron Biologics (Austria) and Galapagos Genomics (Belgium) have made it through to the final round.

13 Aug 2010

Exposure to immune proteins during pregnancy increases risk for schizophrenia in offspring

Infections like the flu are common occurrences during pregnancy, and research has shown that children born to mothers who suffered from flu, viruses and other infections during pregnancy have about a 1.5 to 7 times increased risk for schizophrenia. A new study out of Temple University examines what's behind that link.

13 Aug 2010

NAMI calls for $20 billion relief fund to cover mental health needs resulting from oil spill

The National Alliance on Mental Illness has called on Kenneth Feinberg, the independent claims administrator for the $20 billion relief fund created by BP Oil Company, to cover mental health needs resulting from the company's massive oil spill in the Gulf of Mexico.

12 Aug 2010

ACADIA second-quarter net loss decreases to $4.3 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Alkermes, Inc. today reported financial results for its first quarter of fiscal 2011, which ended on June 30, 2010.

7 Aug 2010

Asynchronous telepsychiatry provides primary-care physicians greater access to psychiatric consultation

A new study by researchers at the UC Davis School of Medicine has found that psychiatrists can accurately assess a patient's mental health by viewing videotaped interviews that are sent to them for consultation and treatment recommendations.

7 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

NARSAD announces 2010 Independent Investigator grants for innovative researchers

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Deficiencies in DNA loop formation can cause multiple diseases: Research

Maternal stress contribute to an elevated risk for depression in offspring: Research

Maternal stress associated with increased risk of schizophrenia in male offspring

NIH awards Brain Plasticity $3.65M to improve cognitive function in people with schizophrenia

Brain stimulation may improve thinking in people with schizophrenia

Depressive Cognition Scale questions can detect cognitive symptoms of early depression

Cortex second-quarter net loss decreases to $0.04 per share

ARYx secures bridge financing, reports decrease in net loss to $3.6M for second-quarter 2010

Recent research on schizophrenia published in journal Current Directions in Psychological Science

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Management of therapy-resistant schizophrenia

EUROPEAN BIOTECHNICA AWARD finalists announced

Exposure to immune proteins during pregnancy increases risk for schizophrenia in offspring

NAMI calls for $20 billion relief fund to cover mental health needs resulting from oil spill

ACADIA second-quarter net loss decreases to $4.3 million

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Asynchronous telepsychiatry provides primary-care physicians greater access to psychiatric consultation

TEMPO study recommends early administration of Azilect in PD patients

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Schizophrenia News and Research

Latest Schizophrenia News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in